Strides Pharma outperforms guidance of 12–15%, aided by strong US business performance in Q4

Strides Pharma Science Ltd. reported a net profit of ₹85.6 crore, compared to a profit of ₹10.4 crore on a year-on-year basis.

Revenue for the quarter increased 14% year-on-year to ₹1,190 crore from last year’s figure of ₹1,043.5 crore.

Revenue from the US business stood at $77 million, grew 23.2% year-on-year.
Strides Pharma’s Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) rose 6.5% to ₹217 crore as against ₹204 crore in the same period a year ago.

Margins, however, contracted by 130 basis points to 18.3% from 19.6% last year.

The board has recommended a final dividend of ₹4 per equity share of Rs 10 each face value (at the rate of 40%) for financial year ended March 31, 2025.

The dividend will be paid within 30 days from the date of shareholders’ approval at the ensuing Annual General Meeting (AGM) of the company.

“Our FY25 revenue grew by 17.2% YoY, outperforming our guidance of 12–15%, aided by strong US business performance. We also surpassed our EBITDA outlook, delivering ₹802.8 crore in FY25, reflecting enhanced operational efficiency and margin resilience post-demerger. We reduced Net debt by ₹512.8 crore, and our Net Debt-to-EBITDA ratio improved to 1.9x, well below the outlook given,” said MD and Group CEO Badree Komandur and Founder and Non-Executive Chairperson Arun Kumar.

Following the earnings announcement, shares of Strides Pharma Science Ltd. climbed over 2% to trade at ₹710.80. The stock is flat on a year-to-date basis.